中文 | English
Return
Total: 5 , 1/1
Show Home Prev Next End page: GO
MeSH:(Olmesartan Medoxomil)

1.Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers.

Harshal Surendra MANDAVDHARE ; Vishal SHARMA ; Kaushal K PRASAD ; Amit KUMAR ; Manish RATHI ; Surinder S RANA

Intestinal Research 2017;15(3):419-421

2.Pharmacokinetics and bioequivalence of two different 20 mg olmesartan tablets: A randomized, single-dose, two-period crossover study in healthy Korean male volunteers.

Jieon LEE ; Anhye KIM ; Kyung Sang YU ; Jae Yong CHUNG ; Sung Vin YIM ; Bo Hyung KIM

Translational and Clinical Pharmacology 2015;23(2):49-53

3.Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension.

Jun-ren ZHU ; Nai-sheng CAI ; Wei-hu FAN ; Ding-liang ZHU ; Ben HE ; Zong-gui WU ; Yuan-nan KE ; Jing-xuan GUO ; Hong MA ; Jun HUANG ; Xin-li LI ; Yun-zhen CHEN

Chinese Journal of Cardiology 2006;34(10):877-881

4.A novel synthesis of olmesartan medoxomil and examination of its related impurities.

Tai-Zhi WU ; Xiao-Hua LIU ; Fu-Li ZHANG ; Mei-Hua XIE

Acta Pharmaceutica Sinica 2006;41(6):537-543

5.Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha and improves vascular remodeling after vascular injury in mouse.

Zhen LI ; Xiao-dong CHEN ; Shao-kai NI ; Jian-wen LI ; Mu-sheng LIN

Chinese Journal of Traumatology 2004;7(1):56-61

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 5 , 1/1 Show Home Prev Next End page: GO